Analyst Reco. Eli Lilly and Company

Equities

LLY

US5324571083

Market Closed - Nyse Other stock markets 04:00:02 2024-06-07 pm EDT			5-day change	1st Jan Change
850 ^USD	+1.52%		+3.61%	+45.82%

Jun. 07	Jefferies Adjusts Price Target on Eli Lilly to $957 From $925	MT
Jun. 07	US FDA Staff Flags Potential Limited Benefit of Eli Lilly's Alzheimer's Disease Drug	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jefferies Adjusts Price Target on Eli Lilly to $957 From $925	Jun. 07	MT
Goldman Sachs Adjusts Price Target on Eli Lilly to $785 From $740	May. 30	MT
Jefferies Adjusts Price Target on Eli Lilly to $925 From $915	May. 23	MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell; Hims & Hers Health to Advance, AMC Entertainment to Decline	May. 21	MT
Argus Adjusts Price Target on Eli Lilly to $840 From $770	May. 14	MT
Redburn Atlantic Adjusts Eli Lilly Price Target to $600 From $540	May. 14	MT
China Merchants Initiates Eli Lilly at Buy Rating With $852 Price Target	May. 08	MT
JPMorgan Adjusts Price Target on Eli Lilly to $900 From $850	May. 01	MT
Wolfe Research Adjusts Price Target on Eli Lilly to $909 From $813	May. 01	MT
Barclays Adjusts Price Target on Eli Lilly and Company to $913 From $810	May. 01	MT
BMO Capital Adjusts Eli Lilly Price Target to $1,001 From $900	May. 01	MT
Leerink Partners Adjusts Price Target on Eli Lilly to $901 From $821	May. 01	MT
Deutsche Bank Adjusts Price Target on Eli Lilly to $725 From $695	May. 01	MT
Truist Raises Price Target on Eli Lilly to $892 From $850, Keeps Buy Rating	May. 01	MT
Goldman Sachs Adjusts Price Target on Eli Lilly to $740 From $723	May. 01	MT
Wells Fargo Adjusts Eli Lilly Price Target to $875 From $825	May. 01	MT
Morgan Stanley Raises Price Target on Eli Lilly to $1,023 From $950 Amid 2024 Guidance Boost, Keeps Overweight Rating	May. 01	MT
Jefferies Adjusts Eli Lilly and Co.'s Price Target to $915 From $895, Keeps Buy Rating	Apr. 30	MT
Jefferies Raises Eli Lilly's Price Target to $895 From $885, Buy Rating Kept	Apr. 17	MT
BMO Raises Price Target on Eli Lilly to $900 From $865	Apr. 12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 12, 2024 at 02:47 pm EDT